% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • checksurshorts checksurshorts Feb 16, 2014 6:39 PM Flag

    Dr Oh still working on IGFBP-3 for Asthma

    Would still love to see something happen with this. Remember "IGFBP-3 blocks the effects of asthma by negatively regulating NF-κB signaling through IGFBP-3R-mediated activation of caspases" from 2011? Looks like he is still working on this. How about a liposomal delivery?

    Targeting IGF-I and IGFBP-3 Signaling Pathways: A Novel Therapeutic Approach for Asthma.

    18:29 EST 16th February 2014

    "Summary of "Targeting IGF-I and IGFBP-3 Signaling Pathways: A Novel Therapeutic Approach for Asthma."

    Insulin like growth factor I (IGF-I) has been recognized to play critical roles in the pathogenesis of asthma while insulin like growth factor binding protein 3 (IGFBP-3) blocks crucial physiologic manifestations of asthma. IGF-I enhances subepithelial fibrosis, airway inflammation, airway hyperresponsiveness (AHR), and airway smooth muscle hyperplasia by interacting with various inflammatory mediators and complex signaling pathways such as intercellular adhesion molecule-1 (ICAM-1), and the hypoxia inducible factor/vascular endothelial growth factor (HIF/VEGF) axis. On the other hand, IGFBP-3 decreases airway inflammation and AHR through IGFBP-3 receptor (IGFBP-3R)-mediated activation of caspases, which subsequently inhibits NF-κB signaling pathway. It also inhibits the IGF-I/HIF/VEGF axis via IGF-I-dependent and/or IGF-I-independent mechanisms. This review will summarize the role of IGF-I and IGFBP-3 in the context of allergic airway disease and discuss the therapeutic potential of various strategies targeting the IGF-I and IGFBP-3 signaling pathways for the management of asthma"

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
11.45+0.12(+1.06%)Jul 29 4:00 PMEDT